公开(公告)号：US20220370491A1

公开(公告)日：2022-11-24

申请号：US17760908

申请日：2020-09-16

Applicant: National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori Yokota ,  Testuya Nagata ,  Hideki Furukawa ,  Takatoshi Yogo ,  Yasuo Nakagawa ,  Shigekazu Sasaki ,  Ryosuke Tokunoh ,  Tomohiro Seki ,  Kosuke Hidaka ,  Fumiaki Kikuchi ,  Osamu Kubo ,  Takahito Kasahara ,  Takuto Kojima ,  Junsi Wang ,  Norihito Tokunaga

IPC: A61K31/713 ,  A61K47/54 ,  A61P25/00 ,  A61K9/00

Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.

公开(公告)号：US11292766B2

公开(公告)日：2022-04-05

申请号：US16713667

申请日：2019-12-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Mariko Hirozane

IPC: C07D215/44 ,  C07D211/36 ,  C07D211/24 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20200247747A1

公开(公告)日：2020-08-06

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto

IPC: C07D207/14 ,  C07D417/06 ,  C07D407/08

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10428023B2

公开(公告)日：2019-10-01

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US09187453B2

公开(公告)日：2015-11-17

申请号：US14388452

申请日：2013-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tetsuya Tsukamoto ,  Yusuke Ohba ,  Takafumi Yukawa ,  Hiroyuki Nagamiya ,  Taku Kamei ,  Norihito Tokunaga ,  Morihisa Saitoh

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/506 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D491/107

CPC classification number: C07D403/04 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US12091410B2

公开(公告)日：2024-09-17

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

CPC classification number: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12071434B2

公开(公告)日：2024-08-27

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Jun Chiba ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04 ,  C07B2200/05

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11987586B1

公开(公告)日：2024-05-21

申请号：US18497602

申请日：2023-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi Hattori ,  Marilena Pira ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Eiji Kimura ,  Norihito Tokunaga ,  Shuhei Ikeda ,  Martin Alexander Pawliczek ,  Noriyuki Tezuka ,  Yasutaka Hoashi ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike

IPC: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.